Daytrana, the first and only transdermal medication approved to treat the symptoms of ADHD, seemed like a great idea. Smack a sticky medicated patch on the body and let your skin soak in the drug.
It seems though that this patch worked just a little too well.
Shire, the pharmaceutical company that holds the global license for Daytrana, pulled their product off the market in response to "mechanical problems" with the patch.
Up to five percent of patients reported trouble removing the release liner from the sticky part of patches. Enhancements are underway to improve the release liner. The FDA last year approved Daytrana for children aged six to twelve years with Attention Deficit Disorder.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment